Integrating Biocompatibility with QMSR: ISO 10993-1:2025 Meets ISO 13485:2016 (Part 3)

Biocompatibility evaluation sits at the intersection of product safety, regulatory compliance, and quality system management. Under the QMSR, which incorporates ISO 13485:2016 by reference, biocompatibility must be fully integrated into your quality management system—not treated as a standalone testing exercise conducted outside your design and risk management processes.

The publication of ISO 10993-1:2025 adds complexity and opportunity. The new standard's risk-based biological evaluation framework aligns well with the QMSR's process-based quality management approach, but requires manufacturers to fundamentally rethink how they plan, execute, and document biocompatibility assessments.

This is Part 3 of our QMSR series. If you haven't read Parts 1 and 2, start there for foundational understanding of the QMSR transition and FDA inspection readiness.

The Shift to Risk-Based Biological Evaluation

ISO 10993-1:2025 represents the most significant change to biocompatibility evaluation in decades. The traditional endpoint matrix that guided testing for over 30 years has been replaced with a systematic biological risk assessment framework.

What Changed in ISO 10993-1:2025

Elimination of the prescriptive testing matrix: Device contact type and duration no longer automatically dictate which biological tests are required. Instead, manufacturers must conduct biological risk assessment to determine what information is needed.

Emphasis on information gathering: The standard prioritizes gathering existing information—material data, literature, chemical characterization, post-market surveillance—before conducting new biological testing.

Strengthened animal welfare requirements: ISO 10993-1:2025 explicitly states that in vivo testing shall not be conducted where valid information on released constituents and degradation products has been addressed by other means and constituents have known and acceptable toxicity profiles.

Enhanced chemical characterization integration: The standard emphasizes using chemical characterization and toxicological risk assessment, particularly for systemic biological endpoints, before defaulting to biological testing.

This risk-based approach aligns naturally with the QMSR's emphasis on process-based quality management, risk management integration, data-driven decision-making, and continuous improvement. Both frameworks require systematic processes that drive decisions based on risk and available information, not prescriptive checklists.

Integrating Biocompatibility into Design Controls

Under the QMSR, design controls provide the framework for systematic device development. Biocompatibility must be embedded throughout design controls, not bolted on at the end.

Design Planning and Inputs

Biological evaluation strategy should be defined during design planning, including contact categorization, biological hazard identification, information needs assessment, and resource allocation for chemical characterization, toxicological risk assessment, and biological testing if needed.

Design inputs must translate biological safety requirements into specifications:

Material specifications defining acceptable materials based on biocompatibility history, chemical composition, and biological risk assessment, including specifications for additives, processing aids, and residuals.

Contact requirements specifying maximum contact area, contact duration, and contact locations based on intended use and biological risk considerations.

Chemical constituent limits establishing maximum acceptable levels for constituents of concern identified through chemical characterization, based on toxicological risk assessment.

Physical characteristics defining requirements for properties affecting biological safety, such as particle size, surface roughness, porosity, or degradation rate.

Design Outputs and Verification

Design outputs must demonstrate that biological safety requirements are met through material selection rationale, complete device description, chemical characterization data, toxicological risk assessment, biological test results (where testing is conducted), and a comprehensive biological evaluation report integrating all information with clear safety conclusions.

Verification activities confirm that design outputs meet design input requirements through material verification, chemical characterization verification, biological test verification, and toxicological assessment review for appropriate methodology and scientifically sound conclusions.

Design Transfer and Change Control

Transfer of biological evaluation requirements to manufacturing ensures production devices maintain biological safety through established process controls, in-process monitoring, acceptance criteria, and change control requirements defining what changes require biological evaluation reassessment.

Changes affecting biological safety—material specifications, manufacturing processes, sterilization methods, component additions, packaging materials, or supplier changes—must be managed through design change control with impact assessment, reassessment requirements, verification of changes, and documentation updates to the design history file, biological evaluation report, and risk management file.

Chemical Characterization and Toxicological Risk Assessment

Chemical characterization has become central to biological evaluation under ISO 10993-1:2025, particularly for addressing systemic biological endpoints.

When Chemical Characterization is Required

ISO 10993-18 and ISO 10993-1:2025 require chemical characterization when material information is insufficient, novel materials are used, devices have complex material systems, long-term contact is involved, or the risk-based evaluation approach requires understanding chemical exposure before determining whether biological testing is necessary.

Extractables vs. Leachables Studies

Extractables studies use exaggerated laboratory conditions to identify the chemical universe that could potentially migrate from the device, representing worst-case chemical exposure.

Leachables studies use conditions simulating actual clinical use to identify and quantify compounds that actually migrate under realistic scenarios, representing expected patient exposure.

ISO 10993-18 provides detailed guidance on study design, including selection of extraction vehicles, extraction temperatures and durations, analytical methods, detection limits, and reporting thresholds.

Toxicological Risk Assessment Process

Chemical characterization data requires expert toxicological interpretation:

Constituent identification determines chemical identity of detected compounds using analytical techniques and spectral libraries.

Exposure estimation calculates patient exposure based on constituent concentrations, device contact area, contact duration, and patient factors.

Hazard identification identifies toxicological hazards using literature, toxicological databases, and structure-activity relationships.

Threshold comparison compares estimated patient exposure to appropriate toxicological thresholds such as Tolerable Daily Intake (TDI) values, Permitted Daily Exposure (PDE) values, Threshold of Toxicological Concern (TTC) values, or No Observed Adverse Effect Levels (NOAELs).

Margin of safety calculation determines safety margins by comparing threshold values to estimated patient exposure with appropriate safety factors.

Risk characterization integrates hazard and exposure information to characterize biological risk for each constituent and the overall device.

This toxicological risk assessment should be documented in the biological evaluation report with clear scientific justification and conservative assumptions.

Systemic vs. Local Biological Endpoints

A critical distinction in biocompatibility evaluation under ISO 10993-1:2025 is understanding which biological endpoints can be addressed through chemical characterization versus which require biological testing.

Systemic Biological Endpoints

Systemic endpoints evaluate risks from compounds absorbed and distributed throughout the body: systemic toxicity, genotoxicity, carcinogenicity, and reproductive and developmental toxicity.

Chemical characterization is highly effective for addressing systemic endpoints because extensive toxicological databases exist for many compounds, dose-response relationships are well-established, threshold of toxicological concern approaches can be applied, and toxicokinetic principles allow estimation of internal dose from external exposure.

For most devices, systematic chemical characterization with toxicological risk assessment can adequately address systemic biological endpoints without animal testing, aligning with ISO 10993-1:2025's animal welfare requirements.

Local Biological Endpoints

Local endpoints evaluate tissue responses at the site of device contact: cytotoxicity, irritation, sensitization, and implantation effects.

Chemical characterization alone is rarely sufficient for addressing local endpoints because toxicological databases for local tissue effects are limited, local responses depend on complex interactions between multiple compounds, physical characteristics significantly impact local responses, synergistic or antagonistic effects cannot be predicted reliably, and insufficient data exists to establish dose-response relationships for local tissue effects.

Practical implication: Even when comprehensive chemical characterization successfully addresses systemic biological risks through toxicological risk assessment, biological testing of local endpoints is almost always still required.

This means devices requiring evaluation of both systemic and local biological endpoints typically need chemical characterization to address systemic risks AND biological testing to address local tissue responses. This integrated approach is necessary because the two methods address fundamentally different types of biological risks.

Biocompatibility in QMSR Quality System Processes

Beyond design controls, biocompatibility must be integrated throughout quality system processes under the QMSR.

Management Review Integration

Management review should include biocompatibility-related inputs such as complaint trends suggesting biological effects, CAPA effectiveness for biocompatibility issues, post-market surveillance findings related to biological safety, and changes affecting materials or biological evaluation adequacy.

Management review outputs should address resource needs for chemical characterization or toxicological expertise, decisions about biocompatibility strategy updates, and actions to address systemic biocompatibility issues identified through quality data.

Internal Audit Coverage

Internal audits should assess biocompatibility integration with design controls, including whether biological evaluation plans are developed during design planning, design inputs include biological safety requirements, and biological evaluation reports are complete and scientifically justified.

Audits should also verify change control effectiveness for biocompatibility, confirming that material changes, supplier changes, and process modifications trigger appropriate biological safety impact assessment and reassessment.

CAPA for Biocompatibility Issues

When complaints or adverse events suggest biological effects, CAPA processes should investigate whether biological mechanisms are plausible, review biological evaluation adequacy, assess whether material or process changes occurred that could affect biological safety, and determine whether additional chemical characterization or biological testing is warranted.

CAPA effectiveness verification should confirm that corrective actions actually addressed biological safety concerns and prevented recurrence.

Post-Market Surveillance

Complaint analysis should identify patterns potentially related to biological effects such as skin reactions, allergic responses, inflammatory responses, or systemic symptoms in temporal relationship to device use.

Literature monitoring should track new toxicological data on materials or constituents used in your device, adverse events reported for similar devices, regulatory actions related to biological effects, and scientific advances in analytical or toxicological methods.

Post-market surveillance data should be integrated into ongoing risk management and biological evaluation reassessment when significant new information emerges.

Documentation Requirements

The QMSR requires comprehensive documentation demonstrating biocompatibility integration with quality system processes.

Biological Evaluation Plan

Document your systematic approach including complete device description, contact categorization per ISO 10993-1:2025, biological hazard identification, information gathering strategy, chemical characterization plan, biological testing strategy with scientific justification, risk assessment approach, and plan review and approval.

The biological evaluation plan should be part of your design and development plan, demonstrating integration with design controls.

Biological Evaluation Report

The biological evaluation report integrates all biological evaluation information with executive summary stating safety conclusions, device and materials description, contact assessment, chemical characterization results, toxicological risk assessment, biological test results where conducted, literature review, risk evaluation, and overall conclusions with scientific justification.

The report should be maintained in the design history file and updated when changes occur or new information becomes available.

Traceability Documentation

Demonstrate traceability throughout your quality system by linking biological safety requirements from user needs through design inputs, outputs, verification, validation, and transfer. Connect biological hazards identified in risk analysis to biological evaluation activities and risk controls. Document how changes were evaluated for biological safety impact and what reassessment was conducted. Show how biological safety-related complaints or issues were investigated and corrected.

This traceability demonstrates systematic integration of biocompatibility with quality system processes, which FDA will evaluate during inspections under Compliance Program 7382.850.

Bottom Line

Integrating biocompatibility evaluation with QMSR quality system requirements demands systematic processes connecting biological risk assessment with design controls, risk management, change control, and post-market surveillance. ISO 10993-1:2025's risk-based biological evaluation framework aligns well with the QMSR's process-based quality management approach, but requires moving beyond historical testing matrices to systematic biological risk assessment.

Chemical characterization with toxicological risk assessment has become central to biological evaluation, particularly for systemic biological endpoints. However, local tissue effects typically still require biological testing even when comprehensive chemical data are available. This integrated approach—combining chemical characterization, toxicological expertise, and appropriate biological testing—provides the most efficient path to demonstrating biological safety while meeting animal welfare requirements.

Success requires embedding biocompatibility considerations throughout your quality system from the earliest design stages, maintaining expert toxicological interpretation of complex data, and ensuring clear documentation demonstrating integration with design controls and risk management processes.

In Part 4 of this series, we'll explore practical implementation strategies for QMSR compliance, including gap analysis frameworks, documentation updates, training requirements, and common pitfalls to avoid.

Expert Biocompatibility Integration and Toxicological Risk Assessment

Successfully integrating biocompatibility evaluation with QMSR quality system requirements requires specialized toxicological expertise and deep understanding of both ISO 10993-1:2025 risk-based frameworks and ISO 13485:2016 quality management principles.

At JL Tox Consulting, we help medical device manufacturers and CROs develop integrated biocompatibility strategies that satisfy QMSR requirements while supporting efficient product development and regulatory submissions.

Our biocompatibility integration services include:

• Biological evaluation planning aligned with ISO 10993-1:2025 and embedded in design controls

• Chemical characterization strategy for extractables and leachables studies per ISO 10993-18

• Toxicological risk assessment of chemical data with health-based threshold comparisons

• Biological testing strategy with scientific justification for testing decisions

• Change control guidance for materials, processes, and suppliers affecting biological safety

• Biological evaluation report preparation integrating chemical, toxicological, and biological data

Contact JL Tox Consulting to integrate biocompatibility expertise into your QMSR quality system:

Email: info@JLTox.com

Phone: (877) 899-6568